FDA expedites review of Novartis drug Promacta for first-line severe aplastic anemia (SAA)
Novartis announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta…
Read More...
Read More...
